RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 118 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $4,963,142 | -52.1% | 278,203 | -21.7% | 0.01% | -54.5% |
Q4 2022 | $10,353,034 | +81.3% | 355,530 | +52.5% | 0.01% | +83.3% |
Q3 2022 | $5,710,000 | +3681.5% | 233,069 | +538.7% | 0.01% | – |
Q2 2022 | $151,000 | -86.5% | 36,492 | -62.4% | 0.00% | -100.0% |
Q1 2022 | $1,117,000 | +66.0% | 96,985 | +206.4% | 0.00% | 0.0% |
Q1 2021 | $673,000 | +128.1% | 31,653 | +188.2% | 0.00% | – |
Q4 2018 | $295,000 | -80.6% | 10,982 | -78.9% | 0.00% | -100.0% |
Q3 2018 | $1,522,000 | +29.5% | 52,161 | +38.8% | 0.00% | 0.0% |
Q2 2018 | $1,175,000 | – | 37,575 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |